A drug delivery system for pyroptosis inhibitor targeting intestinal epithelial cells, and preparation method and application thereof
Through a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, 4-octyl itaconic acid is encapsulated in butyric acid-modified liposomes, solving the problem that drugs in the prior art are difficult to deliver to the inflammatory areas of the colon in the prior art. , effective treatment and side effects of ulcerative colitis have been achieved.
Patent Information
- Application Number
- CN202410291828.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-14
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-03-14
AI Technical Summary
The existing treatment drugs for ulcerative colitis have low remission rates and great side effects in clinical practice, making it difficult to deliver the drugs to the inflammatory areas of the colon, resulting in poor efficacy.
Using a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, 4-octyl itaconic acid is encapsulated in butyric acid-modified liposomes, and liposomes composed of lecithin and cholesterol are realized to intestinal epithelial cells. Targeted delivery uses the specific absorption of butyric acid by intestinal epithelial cells to achieve targeted delivery of the inflammatory site.
Effectively inhibit pyroptosis of intestinal epithelial cells, reduce inflammatory response, increase the concentration of drugs in the inflammatory site, significantly alleviate the symptoms of ulcerative colitis, reduce toxic side effects, and have good safety and targeted effects.
Smart Images

Figure CN118105524B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical preparations and relates to a drug, and in particular to a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells and a preparation method and application thereof. Background Art
[0002] Ulcerative colitis (UC) is a lifelong inflammatory disease that affects the colon and rectum. In recent years, the prevalence of UC has increased significantly, reaching 5 million patients worldwide by 2023, seriously affecting the quality of life of patients and increasing the incidence of colorectal cancer. At present, although some progress has been made in treatment, including 5-aminosalicylic acid (5-ASA), thiopurine drugs and biologics (such as anti-cytokines and anti-integrins), the remission rate is usually 20-30% in clinical trials and 30-60% in actual clinical practice, and the side effects are large (nephrotoxicity, hepatotoxicity, neurotoxicity, etc.). Therefore, there is an urgent need for a drug delivery system to deliver drugs to the inflamed area of the colon to improve efficacy and reduce side effects. Summary of the invention
[0003] The present invention provides a drug delivery system for a pyroptosis inhibitor targeting intestinal epithelial cells, a preparation method and an application thereof, wherein the pyroptosis inhibitor 4-octylitaconic acid is delivered to the inflamed colon site to intervene in the intestinal barrier destruction caused by excessive pyroptosis of intestinal epithelial cells in ulcerative colitis, thereby having a therapeutic effect on ulcerative colitis, thereby overcoming the defects of the prior art.
[0004] To achieve the above objectives, the present invention provides a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, having the following characteristics: the pyroptosis inhibitor drug delivery system is a butyric acid-modified liposome encapsulating 4-octylitaconic acid.
[0005] Furthermore, the present invention provides a drug delivery system for a pyroptosis inhibitor targeting intestinal epithelial cells, which may also have the following characteristics: wherein the liposome comprises lecithin and cholesterol.
[0006] Furthermore, the present invention provides a drug delivery system for a pyroptosis inhibitor targeting intestinal epithelial cells, which may also have the following characteristics: wherein the average particle size of the liposomes targeting intestinal epithelial cells is 100-200 nm.
[0007] The invention provides a preparation method of a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, which has the following characteristics: lecithin, cholesterol, DSPE-PEG, butyric acid and 4-octylitaconic acid are dissolved in ethanol to obtain an ethanol mixture; the ethanol mixture is injected into rapidly stirred water at a constant rate to obtain an ethanol liposome dispersion; and the ethanol in the ethanol liposome dispersion is evaporated to obtain the pyroptosis inhibitor drug delivery system.
[0008] Furthermore, the present invention provides a method for preparing a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, which may also have the following characteristics: wherein the mass ratio of butyric acid to lecithin is 1:1~2; the mass ratio of lecithin, cholesterol and DSPE-PEG is 4:1:2.4.
[0009] Furthermore, the present invention provides a method for preparing a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, which may also have the following characteristics: wherein the stirring speed of the water is 800~1000 r / min.
[0010] Furthermore, the present invention provides a method for preparing a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, which may also have the following characteristics: wherein the concentration of ethanol in the ethanol liposome dispersion is 5-30 v / v %.
[0011] Furthermore, the present invention provides a method for preparing a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, which may also have the following characteristics: wherein the evaporation is rotary evaporation.
[0012] Furthermore, the present invention provides a method for preparing a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells, which may also have the following characteristics: after evaporating the ethanol, excess free drug is removed by differential centrifugation.
[0013] The present invention provides an application of a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells in the preparation of a drug for treating ulcerative colitis.
[0014] The beneficial effects of the present invention are:
[0015] In ulcerative colitis, overactive pyroptosis may lead to excessive inflammatory responses and aggravate disease symptoms. Pyroptosis is a form of cell death that is often accompanied by an inflammatory response inside the cell, including the release of proinflammatory cytokines and phagocytosis of inflammatory cells. Inhibiting pyroptosis may help maintain the integrity of the intestinal mucosa, reduce tissue damage, and may promote the resolution of inflammation. In addition, inhibiting pyroptosis can also reduce the activation of immune cells, thereby reducing the infiltration of inflammatory cells. As a pyroptosis inhibitor, 4-OI can effectively reduce the expression of the pyroptosis execution protein GSDME-NT and reduce the severity of colitis.
[0016] The increased vascular permeability at the site of inflammation and other reasons enable drugs with a certain spatial size, such as drug delivery systems, to be passively targeted to the site of the disease. Among them, liposomes are spherical vesicles formed by phospholipids, and their bilayer structure is similar to that of biological membranes and has amphiphilicity. This enables liposomes to encapsulate water-soluble and fat-soluble substances, and have a self-enclosed structure, which helps prevent the degradation of drugs. In addition, targeted modifications can be performed on the surface of liposomes for targeted drug presentation by liposomes. Compared with other drug delivery systems, liposomes have the advantages of good biocompatibility and in vivo degradability, which can achieve targeted sustained release of drugs in diseased tissues, effectively improve drug utilization, and reduce toxic side effects.
[0017] Preclinical and clinical studies have shown that the short-chain fatty acid butyrate has a significant effect on the relief of colitis animal models and UC patients. In addition, butyrate, as one of the short-chain fatty acids, is the main energy source for intestinal epithelial cells (IECs), and up to 95% of the butyrate produced by microorganisms is absorbed and utilized by the colon. In view of the specific absorption of butyrate by IECs, targeted delivery to IECs can be achieved by modifying the hydrophilic butyrate on the surface of liposomes. On this basis, the encapsulation of the pyroptosis inhibitor 4-OI in butyrate-functionalized liposomes is potentially important for the treatment of UC.
[0018] The pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells of the present invention achieves the effect of treating ulcerative colitis by inhibiting pyroptosis of intestinal epithelial cells. The results of the study showed that butyric acid-modified liposomes (BLipo) can actively target intestinal epithelial cells, and the tail vein injected liposomes show the characteristic of preferential accumulation in the colon, which prompts 4-OI to effectively regulate the pyroptosis process in IECs. The pyroptosis inhibitor drug delivery system of the present invention has a good targeting effect on the site of colon inflammation and good safety. It solves the problems that traditional nanomedicines cannot target the colon and the local drug concentration is low. It can be used for targeted treatment of colon inflammatory diseases and has a good market prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 It is the particle size detection and transmission electron microscopy image of the pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells;
[0020] Figure 2 This is a graph showing the uptake results of liposomes modified with butyrate at different concentrations in intestinal epithelial cells;
[0021] Figure 3 This is a graph showing the distribution of liposomes with and without butyrate modification in vivo;
[0022] Figure 4 This is a graph showing the distribution of liposomes with or without butyrate modification in colon tissue after oral and intravenous injection;
[0023] Figure 5 This is a diagram showing the therapeutic effect of the pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells on colitis;
[0024] Figure 6 This is a graph showing the CCK8 test results of the pyroptosis inhibitor drug delivery system in terms of the safety of intestinal epithelial cell proliferation. DETAILED DESCRIPTION
[0025] The present invention is further described below in conjunction with specific embodiments.
[0026] This embodiment provides a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells. The pyroptosis inhibitor drug delivery system is a butyric acid-modified liposome (4-OI / BLipo) encapsulating 4-octylitaconic acid (4-OI).
[0027] The pyroptosis inhibitor drug delivery system was prepared by a modified ethanol injection method, as follows: 10 mg of lecithin, 2.5 mg of cholesterol, 6 mg of DSPE-PEG, 5 mg of butyric acid, and 1 mg of 4-OI were dissolved in 500 μL of anhydrous ethanol. The ethanol mixture was injected at a constant rate into 4.5 mL of rapidly stirred ultrapure water at a stirring speed of 900 r / min to produce an ethanol liposome dispersion with a 10% ethanol concentration (volume / volume). The obtained ethanol liposome dispersion was transferred to a rotary evaporator to remove ethanol. Subsequently, the solution was centrifuged (12000 rpm, 20 min) to precipitate unencapsulated drugs or large particles to obtain the pyroptosis inhibitor drug delivery system. For cell and animal experiments, the pyroptosis inhibitor drug delivery system was suspended in ultrapure water, sterilized by filtration through a 0.45 μm filter, and stored at 4°C.
[0028] The above pyroptosis inhibitor drug delivery system was diluted 1:5, and its particle size was measured by dynamic light scattering (DLS) and electrophoretic light scattering (ELS) using Zetasizer Nano, respectively. The morphological characteristics of 4-OI / BLipo were visualized by transmission electron microscopy. Figure 1 Electron microscopy analysis showed a double-layer liposome structure, and particle size analysis showed that the particle size was between 100 and 200 nm.
[0029] The pyroptosis inhibitor drug delivery system is used to treat ulcerative colitis. The efficacy experiment is as follows:
[0030] Coumarin 6 was used as a fluorescent probe to replace 4-OI in the pyroptosis inhibitor drug delivery system. Butyric acid-modified liposomes with different concentrations were prepared. Lipo@C6, B(20%)Lipo@C6, B(50%)Lipo, and B(100%)Lipo (the mass ratios of lecithin to butyric acid were no butyric acid, 5:1, 2:1, and 1:1, respectively) were added to intestinal epithelial cells NCM460 for treatment. The uptake of the drug delivery system (green) by NCM460 was observed under a laser confocal microscope at 3 and 6 hours, respectively. The results are shown in Figure 2. Figure 2 The experimental results show that compared with simple liposomes, butyrate-modified liposomes were taken up more by NCM460 in the same period of time, indicating that butyrate-modified liposomes have stronger targeting to intestinal epithelial cells.
[0031] Dextran sodium sulfate (DSS) was used to induce colitis in mice, and then the drug was administered through the tail vein. Six hours later, in vivo imaging of the mice was performed. The near-infrared dye DiR was used as a fluorescent probe to replace 4-OI in the pyroptosis inhibitor drug delivery system, and liposomes without butyrate modification were prepared to study the targeting distribution characteristics of butyrate-modified liposomes in colitis mice. The results are shown in the figure. Figure 3 As shown by Figure 3 It can be seen that 6 hours after administration, the butyrate-modified liposomes injected through the tail vein were still largely enriched and retained in the colon, while the simple liposome group was almost completely metabolized.
[0032] BLipo was labeled with coumarin 6 and then administered orally (Oral) or intravenously (IV) to colitis model mice. After 12 hours, the inflamed colon of the mice was taken and cut longitudinally into 2 mm thick slices for ex vivo fluorescence imaging. The distribution pattern of intravenously injected BLipo@C6 was significantly different from that of oral administration. As shown in the figure, compared with Lipo@C6, the residence time of BLipo@C6 in the intestine was enhanced, and intravenous injection resulted in a wider distribution in the inflammatory site. In addition, semi-quantitative analysis by ImageJ software showed that intravenously injected BLipo@C6 crossed the damaged intestinal epithelial screen to reach the stromal layer, which was densely infiltrated with immune cells.
[0033] 2% DSS was added to the drinking water of mice to establish the model. The mice were intravenously administered with a dose of 6 mg / kg each time. Figure 5 The results showed that tail vein injection of 4-OI / BLipo could significantly restore the weight loss, disease activity score (DAI) and colon length of colitis mice, while the free 4-OI group had no significant therapeutic effect.
[0034] The pyroptosis inhibitor drug delivery system was used to treat intestinal epithelial cells NCM460 at different concentrations, and CCK8 toxicity was tested 48 hours later. The results are as follows: Figure 6 As shown. The results showed that liposomes had no significant inhibitory effect on cell proliferation, proving the safety of the constructed pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells.
[0035] The above experimental results show that the present invention provides a drug targeting intestinal epithelial cells for treating ulcerative colitis, which is used for tail vein targeted treatment of ulcerative colitis by leveraging the specific uptake of butyrate by intestinal epithelial cells.
[0036] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the reagents, materials and operating procedures used herein are reagents, materials and conventional procedures widely used in the corresponding fields.
[0037] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Application of a pyroptosis inhibitor drug delivery system targeting intestinal epithelial cells in the preparation of a drug for treating ulcerative colitis, characterized in that: The only active ingredient of the pyroptosis inhibitor drug delivery system is a butyric acid-modified liposome encapsulating 4-octylitaconic acid; the liposome comprises phosphatidylcholine and cholesterol; The preparation method of butyric acid-modified liposomes encapsulating 4-octylitaconic acid is as follows: dissolving lecithin, cholesterol, DSPE-PEG, butyric acid and 4-octylitaconic acid in ethanol to obtain an ethanol mixture; injecting the ethanol mixture into rapidly stirred water at a constant rate to obtain an ethanol liposome dispersion; evaporating and removing ethanol in the ethanol liposome dispersion to obtain the pyroptosis inhibitor drug delivery system; the mass ratio of butyric acid to lecithin is 1:1~2; the mass ratio of lecithin, cholesterol and DSPE-PEG is 4:1:2.
4.
2. The use according to claim 1, characterized in that: in, The average particle size of the liposome is 100-200 nm.
3. The use according to claim 1, characterized in that: in, The stirring speed of the water is 800-1000 r / min.
4. The use according to claim 1, characterized in that: in, The concentration of ethanol in the ethanol liposome dispersion is 5-30 v / v %.
5. The use according to claim 1, characterized in that: in, The evaporation is rotary evaporation.
6. The use according to claim 1, characterized in that: in, After evaporation of the ethanol, excess free drug was removed by differential centrifugation.
